Eiger BioPharmaceuticals, Inc.
EIGR
EIGR was delisted on the 10th of April, 2024.
1 hedge funds and large institutions have $1.24M invested in Eiger BioPharmaceuticals, Inc. in 2024 Q3 according to their latest regulatory filings, with funds opening new positions, increasing their positions, 0 reducing their positions, and 1 closing their positions.
33% less capital invested
Capital invested by funds: $1.85M → $1.24M (-$608K)
50% less funds holding
Funds holding: 2 → 1 (-1)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Osaic Holdings
Scottsdale,
Arizona
|
-$543 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
PBM
1
Propel Bio Management
Los Angeles,
California
| $1.24M | – | – | – |
|
|
2
Osaic Holdings
Scottsdale,
Arizona
| – | -$543 | -43 | Closed |
|
EIGR Hedge Fund Activity: Q3 2024 in Review
1 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Eiger BioPharmaceuticals, Inc. (EIGR) for Q3 2024, worth a combined $1.24M — down 33% from $1.85M a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of EIGR and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.
The largest seller was Osaic Holdings, exiting entirely with an estimated $543 sold.
- 1 institutional investor held Eiger BioPharmaceuticals, Inc. (EIGR) as of Q3 2024, down from 2 in Q2 2024.
- Funds reported $1.24M of Eiger BioPharmaceuticals, Inc. stock for Q3 2024, down 33% quarter-over-quarter.
- 0 funds opened new Eiger BioPharmaceuticals, Inc. positions in Q3 2024 and 1 closed out, a net change of -1 holder.
- The largest Eiger BioPharmaceuticals, Inc. seller in Q3 2024 was Osaic Holdings, an estimated $543 sold.
Based on aggregated 13F filings for Q3 2024.